James Manuso joins the US-based biotechnology organisation
James Manuso, chief executive of SuperGen, a US developer of novel cancer therapies, has been elected to the board of the Biotechnology Industry Organization (BIO), based in Washington, DC.
BIO’s board includes members of the governing boards for each of the organisation’s four sections: health, emerging companies, industrial and environmental and food and agriculture. Manuso has joined BIO’s health section governing board.
In addition, Manuso will serve on the BIO board Standing Committee on International Affairs.
SuperGen has been a member of BIO since 2003.
Manuso has been SuperGen chairman, president and chief executive since January 2004. He is co-founder and immediate past president and chief executive of Galenica Pharmaceuticals.
The Biotechnology Industry Organization (BIO) represents more than 1,100 biotechnology companies, academic institutions, biotechnology centres and related organisations across the US and in more than 30 other nations.
BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products.